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Abstract
Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or
refractory to bortezomib and lenalidomide, carries a poor prognosis. The healthcare costs
of DRMM have not previously been reported. We analyzed detailed medical resource utili-
zation (MRU) costs, drug costs and outcomes for 39 UK patients receiving standard DRMM
therapy. Median OS in this cohort was 5.6 months. The mean cost of DRMM treatment plus
MRU until death was £23,472 [range: £1,411–£90,262], split between drug costs £11,191
and other resource use costs £12,281. The cost per assumed quality-adjusted life year
(QALY) during DRMMwas £66,983. These data provide a standard of care comparison
when evaluating the cost-effectiveness of new drugs in DRMM.
Introduction
Patients with treatment-refractory malignancy have poor outcomes and high healthcare costs.
In Multiple Myeloma (MM), the introduction of the proteasome inhibitor bortezomib and
immunomodulatory drugs (IMiDs) thalidomide and lenalidomide has improved survival over
the last decade [1], but increased the cost of treatment. While these drugs can result in remis-
sion, most patients will relapse with increasing symptom burden and worsening prognosis [2].
Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or
refractory to bortezomib and lenalidomide [3], carries a poor prognosis and therapeutic
options remain limited. An IMWG retrospective analysis of patients who relapsed following
bortezomib and at least one of the IMiDs showed a median overall survival (OS) and progres-
sion-free survival (PFS) of 9 months and 5 months respectively [4]. Only those potentially eligi-
ble for further clinical trials with Eastern Cooperative Oncology Group Performance Status
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Studies of healthcare costs for relapsed and/or refractory MM patients receiving bortezomib
and/or lenalidomide based regimens have been undertaken in a variety of countries, using
‘real-world’ data and/or economic modelling, often from patients enrolled in clinical trials
[5–9]. However, none of them address MRU for patients relapsed after bortezomib and lenali-
domide. The third-generation IMiD pomalidomide and second-generation proteasome inhibi-
tor carfilzomib have recently been licensed and have efficacy in DRMM [10]. The cost burden
and clinical outcomes outside of trials of this phase of the disease has never been established, so
new therapies with efficacy in DRMM have no published benchmark against which to judge
cost-effectiveness. To ensure resources are allocated appropriately, the cost-effectiveness evalu-
ation of these therapies in the DRMM setting must involve non-clinical trial, real world MRU
data from relevant patients. Our data provides a standard of care comparison when evaluating
cost-effectiveness of new drugs in DRMM.
Methods
Ethics Statement
All patients whose data were included in this study had provided written consent for the use of
their anonymised data for the purposes of audit and service improvement by the Thames Val-
ley Cancer Network, UK. This study was appropriately registered using the clinical audit proj-
ect proposal system at Oxford University Hospitals NHS Trust, UK. The Clinical Audit Lead
reviewed and approved the proposal, and in line with the UK NHS National Research Ethics
Service (NRES) guidance, deemed it not to require IRB or ethics committee approval.
Anonymised data on clinical outcomes, anti-myeloma therapies prescribed and MRU were
obtained for 39 DRMM patients pre-treated with or intolerant to bortezomib and lenalidomide
in the Thames Valley Cancer Network, UK from 2011 to 2014 (Table A in S1 File). Based on
the UK National Institute for Health and Care Excellence (NICE) guidelines, bortezomib-
based therapy was used for first relapse unless contraindicated. Lenalidomide-dexamethasone
combination was approved for second and subsequent relapse. Relapsed myeloma patients
were identified using pharmacy-generated lists of all sequential lenalidomide recipients
between January 2011 and July 2013 at Oxford University Hospitals and the Royal Berkshire
Hospital, Reading, UK. The strategy of using hospital pharmacy dispensing data to identify
subjects ensured all lenalidomide recipients during the study period were included in the
analysis, as long as they had Multiple Myeloma and had progressed on or were refractory to
lenalidomide, according to IMWG criteria [11]. 34 (87%) patients were pre-treated with lenali-
domide and bortezomib, and had relapsed following, or failed to tolerate both therapies. 5
patients had not received bortezomib due to pre-existing peripheral neuropathy, sufficiently
severe to contraindicate its use.
OS and PFS were calculated from the start date of the first therapy following relapse after
lenalidomide (‘1st DRMM therapy’) until either IMWG criteria for progression/relapse were
reached or death. The data censor date was 10 January 2014 for patients still alive. For each
patient the following occurrences of MRU were retrieved from health care records from the
start of each successive DRMM therapy until death or censoring: detailed drug regimens, out-
patient clinic and chemotherapy unit attendances, inpatient/hospice admissions, supportive
therapies, medical procedures, radiological investigations, blood product transfusions and
blood tests. Costings were calculated using NHS reference costs 2012–13. These were combined
to give one MRU cost from the start of DRMM therapy to death or censoring, using a micro-
costing approach. Drug costs were separately calculated for each successive DRMM therapy.
DRMM: Outcomes and Real World Healthcare Costs
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Results
When offered DRMM therapy, 67% of patients preferred active treatment to palliative care
(Table 1). The median age of those who chose palliative care was 73.2 years compared to 59.9
for active therapy (p<0.001). The first DRMM treatment regimen was typically bendamustine,
thalidomide and dexamethasone (43.6%) as published previously [12]. Retreatment with borte-
zomib (15.4%) or lenalidomide (33.3%) based regimens was used if poor bone marrow reserve
precluded bendamustine use and suitable clinical trial alternatives were lacking.
Regimen choice was made by the treating clinician and based on ECOG PS and response/
side effect profile of prior therapies. Third-generation IMiDs and second-generation protea-
some inhibitors were not routinely available to this cohort, excepting pomalidomide in one
patient. Two patients who had not previously received bortezomib due to neuropathy did
receive it at DRMMwith no recorded worsening of neuropathy; one had progressive disease
despite its use and the other had a partial response of 6 months duration.
Median PFS was 5.2 months and median OS was 5.6 months from start of DRMM therapy
(Fig 1). These statistics reflect a steep drop in survival early on with a few patients surviving sig-
nificantly longer. 24/39 (61.5%) patients had died by the end of follow-up, of whom 79% died
in hospital/ hospice. The cohort was deemed too small and heterogeneous for analysis of regi-
men effect on survival.
MRU was high in this cohort in comparison with that usually observed at earlier lines of
therapy (Table 2). 60 inpatient hospital admissions occurred during DRMM therapy in 39
patients. Admissions lasted 9.3 days on average, for indications including pain management,
renal failure and most commonly neutropenic fever, with some cases of culture-confirmed sep-
ticaemia. Prolonged inpatient admissions, frequent AEs and high transfusion requirements
reflect a poor quality of life (QoL) among these patients (Table 3). The most common recorded
Grade 3–4 adverse events (AEs) were anaemia (43.6%), thrombocytopenia (28.2%) and bone
pain (33.3%) (Table 3, Table B in S1 File).
The mean total MRU cost per patient from start of DRMM therapy until death or censor
was £12,281 (Table 2). This comprises: clinic attendances £5,007 (41%); inpatient admissions
£2,884 (20%); transfusions £2,479 (23%); supportive therapy £1,454 (12%); radiology/proce-
dures £323 (3%); blood tests £151 (1%). The mean drug cost of DRMM therapy is estimated to
be £11,191 per patient. The mean total cost of treatment plus MRU is therefore £23,472 [range:
£1,411 - £90,262]; £760 per week of life with DRMM. Formal QoL data is lacking in this retro-
spective cohort but has been previously published for DRMM patients in the MM-003 trial
[13]. Assuming that QoL was the same in this cohort (utility 0.59) and remained constant
throughout patients’ lifetimes, our analysis indicated a cost per QALY of £66,983.
Conclusion
Although the small sample size of this cohort limits the ability to draw definitive survival con-
clusions, PFS and OS were poor, with a wide range due to the inclusion of all patients whether
treated with active or palliative intent, but were similar to published examples [4]. Despite the
poor outcomes, up to two thirds of DRMM patients want to be treated with active intent to
improve survival, reiterating the need to develop therapies that give patients an improved prog-
nosis, whilst being cost-effective and well tolerated in a heavily pre-treated patient group. The
heterogeneity of this cohort is acknowledged but intentional, representing a typical real world
hospital cohort of patients, where a range of therapeutic options must be employed, con-
strained by varying patient-related factors such as ECOG PS, drug tolerance, social situation
and patient choice.
DRMM: Outcomes and Real World Healthcare Costs
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Table 1. Patient characteristics.
Median age at diagnosis, years (range)* 64.3 (45–79)
Median age by treatment intent: Active/ Palliative 59.9 (n = 26)/ 73.2 (n = 13)
Isotope: IgA/ IgG/ Light chain 7 (51.3%)/ 20 (18.0%)/ 12 (30.8%)
ISS stage I at diagnosis 6 (15.4%)
ISS stage II at diagnosis 9 (23.1%)
ISS stage III at diagnosis 10 (25.6%)
ISS stage at diagnosis unknown 14 (35.9%)
Previous thalidomide-based treatment 34 (87.2%)
Previous bortezomib-based treatment 34 (87.2%)
Previous lenalidomide-based treatment 39 (100.0%)
Previous high dose melphalan with stem cell rescue 17 (43.5%)
Previous additional alternative treatment(s):
Vincristine-based regime 7 (17.9%)
Melphalan-based regime 5 (12.8%)
Allograft 1 (2.6%)
Median years from diagnosis to DRMM point (range)* 4 years 9.5 months (6.5 mo– 10.5 y)
Median number regimes prior to DRMM (range) 4 (2–5)
1st DRMM therapy contained bendamustine 17 (43.6%)
1st DRMM therapy contained bortezomib 6 (15.4%)
1st DRMM therapy DT-PACE 1 (2.6%)
1st DRMM therapy contained lenalidomide 13 (33.3%)
No treatment given at DRMM 2 (5.1%)
2nd DRMM therapy (n = 7):
Bendamustine, thalidomide, dexamethasone 2 (28.6%)
Melphalan, dexamethasone 2 (28.6%)
Thalidomide-based regime 2 (28.6%)
Pomalidomide, dexamethasone 1 (14.3%)
3rd DRMM therapy (n = 4):
Bortezomib, cyclophosphamide, dexamethasone 2 (50.0%)
Bortezomib, melphalan, prednisone 1 (25.0%)
Bendamustine, thalidomide, dexamethasone 1 (25.0%)





PD or death within first month 14 (35.9%)
Unknown 1 (2.6%)
Duration of treatment (SD) 104.9 days (63.8)
Response to 2nd DRMM therapy:
PR 3 (42.9%)
SD 2 (28.6%)
PD or death within first month 2 (28.6%)
Response to 3rd DRMM therapy:
PR 2 (50.0%)
PD or death within first month 1 (25.0%)
(Continued)
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This is the first report of non-clinical trial based ‘real-world’MRU cost analysis in the
setting of DRMM. These patients have high MRU costs. A comparable cost analysis report
relates to a subset of 54 ‘4th line’ real world relapsed/refractory patients in a Netherlands study,
recruited from a previous trial cohort [7]. However, it is likely that this cohort (data collected
Table 1. (Continued)
Unknown 1 (25.0%)
*Date of diagnosis unavailable in 2 cases. ISS: International Staging System; DRMM: Double Relapsed
and/or Refractory Multiple Myeloma; CR: Complete response; VGPR: Very good partial response; PR:
Partial response; SD: Stable disease; PD: Progressive disease [11]
doi:10.1371/journal.pone.0136207.t001
Fig 1. Kaplan Meier curve showing overall survival, progression free survival and time to treatment failure.
doi:10.1371/journal.pone.0136207.g001
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Table 2. Medical Resource Utilisation Costs of Double Relapsed and/or Refractory Multiple Myeloma Therapy.




1st DRMM therapy (per 28 day cycle)a DT-PACE 1/39 £946
Bendamustine-based 17/39 £1,332
No active treatment 2/39 £0
Average £2,532
Ben/ Thal/ Dex 2/39 £853
Mel/ Dex 2/39 £133
2nd DRMM therapy (per 28 day cycle) a Thal 2/39 £298
Pom/ Dex 1/39 £8,887
No 2nd DRMM therapy 32/39 £0
Average £294
Bor/ Cyc/ Dex 2/39 £4,118
3rd DRMM therapy (per 28 day cycle) a Bor/ Mel/ Pred 1/39 £3,847
Ben/ Thal/ Dex 1/39 £1,983
No 3rd DRMM therapy 35/39 £0
Average £361
Total 1st DRMM therapy drug costs (all cycles) £9,527
Total 2nd DRMM therapy drug costs (all cycles) £807
Total 3rd DRMM therapy drug costs (all cycles) £857
Total drug costs (all cycles) £11,191
Occurrences during DRMM periodd
MRU Category MRU Item Cost per Patient Range
Mean SD
Other MRU costs
Inpatient admissions Night as inpatient 9.3 7.9 £2,463 £0, £16,169
Outpatient 4.2 4.1 £630 £0, £3,012
Attendances Day therapy unit 12.8 9.7 £4,331 £0, £11,848
Triage, not admitted 0.4 0.9 £46 £0, £344
CT scan 0.4 0.8 £42 £0, £435
Invasive and radiological procedures MRI scan 0.3 0.6 £57 £0, £343
X-ray 1.1 2.7 £31 £0, £311
Maxillofacial 0.1 0.2 £21 £0, £406
Otherb 0.3 0.5 £172 £0, £3,225
Supportive therapy Bisphosphonatec 2.6 2.5 £217 £0, £713
Radiotherapy 1.1 3.6 £1,237 £0, £21,643
Transfusion Red blood cells (units) 5.9 6.0 £1,684 £0, £5,993
Platelets (units) 2.3 3.8 £1,200 £0, £6,784
Full blood count 21.6 13.0 £65 £0, £196
Blood tests Biochemistry 20.6 15.6 £26 £0, £110
Immunology 4.4 2.9 £22 £0, £60
Microbiology 5.6 7.0 £38 £0, £278
Total other MRU costs £12,281 £995,
(Continued)
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from 2001 to 2009) included patients who received bortezomib (n = 12) and/or lenalidomide
(n = 20) for the first time at 4th line, as they were first made available during the study period.
At €32,889 per patient (range: €1,055–€144,967), costs reported in that study are comparable
to our findings. However an estimated cost per QALY of £66,983 is a significant increase on
that reported by Brown et al in a UK study of the cost effectiveness of Lenalidomide-based
therapies after one prior therapy [5], where cost was £30,153/QALY. The difference reflects the
limited benefit to survival of any current therapy at DRMM, and the higher MRU costs at this
later stage of disease.
Table 2. (Continued)
£40,274
Total (drug costs and other MRU costs) £23,472 £1,411,
£90,262
MRU: Medical Resource Utilization; DRMM: Double Relapsed and/or Refractory Multiple Myeloma; Ben: Bendamustine; Thal: Thalidomide; Dex:
Dexamethasone; Mel: Melphalan; Pom: Pomalidomide; Bor: Bortezomib; Cyc: Cyclophosphamide; Pred: Prednisone.
aDrug costs have been calculated as the average of all patients undertaking each regimen. Dosing changes have been incorporated where provided.
Additional dosing regimen details have been taken from product SPCs. Costs are taken from BNF or eMIT; and are applied using the appropriate pack/
vial size. The average surface area of a patient (used for IV therapies) is taken from the MM-003 clinical trial (approximately 1.86m2). Differences in costs
of the same treatment between treatment lines are caused by differences in dosing for individual patients.
bOther medical procedures consisted of: 1 vertebroplasty; 1 facet joint injection; 1 endoscopy; 1 bronchoscopy; 1 hip fracture repair under general
anaesthetic; 2 PET scans and 4 ultrasound scans.
cBisphosphonate costs calculated assuming all patients on bisphosphonates are on an average dose. The figure shows the approximate number of cycles
for which patients are on bisphosphonate treatment.
dAll MRU occurrences were recorded from initiation of 1st DRMM therapy until the end of follow up (or death)
doi:10.1371/journal.pone.0136207.t002
Table 3. Surrogates of Quality of Life during Double Relapsed and/or Refractory Multiple Myeloma
Therapy.
Surrogates of Quality of Lifea Number of patients





Febrile neutropaenia 6 (15.4%)
Bone pain 13 (33.3%)
Acute renal failure 4 (10.3%)
Dehydration / vomiting / diarrhoea 2 (5.1%)
Admissions during DRMM therapy (SD) 1.3 per patient (1.1)
Duration of admissions (SD) 9.3 days (7.9)
Outpatient clinic appointments during DRMM therapy (SD) 4.2 per patient (4.1)
Day therapy unit visits during DRMM, including CT & MRI (SD) 12.2 per patient (9.7)
RBC units during DRMM therapy (SD) 5.9 per patient (6.0)
Platelet units during DRMM therapy (SD) 2.3 per patient (3.8)
aAll Surrogates of Quality of Life were recorded from initiation of 1st DRMM therapy until the end of follow
up (or death)
bAdverse events with no recorded grade are assumed to be grade 3 or 4.
doi:10.1371/journal.pone.0136207.t003
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Compared with a decade ago, the price range of new anticancer agents has more than dou-
bled [14], and the cost of care analysis of these agents is imperative. New MM therapies carfil-
zomib and pomalidomide have been priced significantly higher than currently available anti-
myeloma drugs. Any subsequent cost benefit analysis comparisons performed in DRMM
patients must be set in the context of the high background MRU as observed in our cohort. It is
highly relevant that the cost per assumed QALY in this cohort is double that usually accepted
by the UK National Institute for Health and Care Excellence [15]. In addition to improving
survival, therapies that induce higher response rates or arrest disease progression could poten-
tially increase therapy costs, but lower MRU costs and improve QoL if progression is halted.
Biomarkers that focus use of new drugs to cohorts of patients where maximum benefit is
obtained would improve cost-effectiveness further. New treatments should be compared with
real-world non-trial outcomes such as that provided here, to give a realistic picture of the value
of these new drugs.
Supporting Information
S1 File. Table A: Complete Data collected (excepting adverse events) on 39 patients with
Double Refractory Multiple Myeloma. Table B: Adverse Events recorded for 39 patients
with Double Refractory Multiple Myeloma.
(XLS)
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